N-t-butyl-2,2-dimethylpropylamine | 58471-09-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-t-butyl-2,2-dimethylpropylamine
• 英文别名: N-tert-Butylneopentylamine；tert-Amyl-tert-butylamin；Neopentyl, t-butyl amine；N-tert-butyl-2,2-dimethylpropan-1-amine
• CAS: 58471-09-3
• 化学式: C₉H₂₁N
• 分子量: 143.272
• InChiKey: JPTZOFZNRFPMPG-UHFFFAOYSA-N

物化性质

• 沸点：
  155.8±8.0 °C(Predicted)
• 密度：
  0.770±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N-t-butyl-2,2-dimethylpropylamine 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 乙醚 、 氯仿 、 二丁醚 为溶剂， 反应 10.0h， 生成 N-tert-Butyl-N-neopentylbenzamine
  参考文献：
  名称：

  Conformational studies by dynamic NMR. 39. Clefts in simple acyclic organic molecules. Correlated stereodynamics of N-tert-alkylbenzylamines studied by dynamic NMR spectroscopy, x-ray diffraction, and molecular mechanics calculations

  摘要：

  In N-tert-butyl-N-neopentylbenzylamine (1), the slowing of four processes can be observed in the NMR spectrum at low temperature. The rate constant for 120-degrees rotation of the N-tert-butyl group is three times that for 180-degrees rotation of the phenyl group at all temperatures studied, suggesting correlated rotation of these groups. Barriers for the two processes specified are 6.8 and 7.1 kcal/mol, respectively, at -120-degrees-C. The barrier to interconversion of enantiomeric configurations by nitrogen inversion plus rotation is 9.2 kcal/mol at -77-degrees-C. The barrier to rotation about the tert-butyl-CH2 bond is 5.95 kcal/mol at -143-degrees-C. The anti arrangement of the t-BuNCH2-t-Bu part of the molecule greatly limits the space available for the benzyl substituent, and only one conformation about the N-benzyl bond is populated. Molecular mechanics calculations suggest that the benzyl group occupies a pocket or cleft, defined by the tert-butyl groups, undergoing several kcal/mol of repulsion and attraction from opposite directions. The barrier to rotation about the phenyl-CH2 bond is unprecedentedly high for a simple molecule but is comparable to or smaller than some found in polypeptides of rigid tertiary conformation, where concerted rotation is also a feature. Similar results obtain when either tert-butyl group is replaced by an adamantyl group to give N-(1-adamantyl)-N-neopentylbenzylamine (2) and N-tert-butyl-N-(1-adamantylmethyl)benzylamine (3). A crystal structure determination of 2 shows a conformation very close to that predicted by molecular mechanics calculations.

  DOI：

  10.1021/jo00005a016
• 作为产物：
  描述：

  N-(tert-butyl)-2,2-dimethylpropan-1-imine 在 氢气 、 C₃₆H₅₆AlN₂⁽¹⁺⁾*C₂₄BF₂₀^(1-) 作用下， 以 氘代苯 、 氯苯 为溶剂， 60.0 ℃ 、150.0 kPa 条件下， 反应 16.0h， 生成 N-t-butyl-2,2-dimethylpropylamine
  参考文献：
  名称：

  阳离子铝络合物作为亚胺加氢催化剂

  摘要：

  强路易斯酸性阳离子铝络合物，通过β-二亚胺基（BDI）的配体和游离的路易斯碱稳定的，已被制备成其B（C 6 ˚F 5）4 -的盐和被研究用于亚胺氢化的催化活性。R1，R2 BDI配体（R1，R2 BDI = HC [C（R1）N（R2）] 2）上的主链（R1）和N（R2）取代基会影响空间和路易斯酸度。配体沿着行体积增大Me中，DIPP BDI <我，DIPeP BDI≈吨卜，DIPP BDI <吨卜，DIPeP BDI; DIPP = 2,6‐C（H）Me 2‐苯基，DIPeP = 2,6‐C（H）Et 2-苯基。Gutmann-Beckett检验显示的受主数为：（t Bu，DIPP BDI）AlMe + 85.6，（t Bu，DIPeP BDI）AlMe + 85.9，（Me，DIPP BDI）AlMe + 89.7，（Me，DIPeP BDI）AlMe + 90.8，（Me，DIPP BDI）AlH

  DOI：

  10.1002/chem.202100641

文献信息

• THERAPEUTIC COMPOUNDS
  申请人：REGENTS OF THE UNIVERSITY OF MINNESOTA

  公开号：US20160376238A1

  公开（公告）日：2016-12-29

  The invention provides compounds of formula (I): wherein, A, C, D, X, and Y have any of the values defined in the specification, and salts thereof. The compounds are SIRT2 inhibitors and are useful for treating SIRT2 associated conditions.

  这项发明提供了式（I）的化合物： 其中，A、C、D、X 和 Y 可以取规范中定义的任何值，以及它们的盐。这些化合物是SIRT2抑制剂，可用于治疗与SIRT2相关的疾病。
• A General One-Pot, Three-Component Mono N-Alkylation of Amines and Amine Derivatives in Lithium Perchlorate/Diethyl Ether Solution
  作者：Akbar Heydari、Hossein Tavakol、Saied Aslanzadeh、Jamshid Azarnia、Nafiseh Ahmadi

  DOI：10.1055/s-2005-861798

  日期：——

  reductive monoalkyl- ation of amines and amine derivatives with aldehydes is reported. Treatment of aldehydes with primary amines, secondary amines, O- trimethylsilylhydroxylamine, and N,N-dimethylhydrazine in lithi- um perchlorate/diethyl ether and trimethylsilyl chloride, followed by BH3·NEt3 reduction, and straightforward workup afforded sec- ondary amines, tertiary amines, N-substituted hydroxylamines

  报道了一种用醛还原单烷基化胺和胺衍生物的有效通用程序。在高氯酸锂/乙醚和三甲基氯硅烷中用伯胺、仲胺、O-三甲基甲硅烷基羟胺和 N,N-二甲基肼处理醛，然后进行 BH3·NEt3 还原，直接后处理得到仲胺、叔胺，N-取代的羟胺和肼，分别。α-氨基酯与醛的还原烷基化选择性地提供相应的N-单烷基化α-氨基酯。
• Methylphenidate-Prodrugs, Processes of Making and Using the Same
  申请人：KemPharm, Inc.

  公开号：US20150266911A1

  公开（公告）日：2015-09-24

  The present technology is directed to prodrugs and compositions for the treatment of various diseases and/or disorders comprising methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof. In some embodiments, the conjugates further include at least one linker. The present technology also relates to the synthesis of methylphenidate, or methylphenidate derivatives, conjugated to at least one alcohol, amine, oxoacid, thiol, or derivatives thereof or combinations thereof.

  目前的技术是针对前药和组合物的，用于治疗包括甲基苯丙胺或甲基苯丙胺衍生物的至少与醇、胺、羧酸、硫醇或其衍生物结合的各种疾病和/或紊乱。在某些实施例中，这些结合物还包括至少一个连接剂。该技术还涉及合成甲基苯丙胺或甲基苯丙胺衍生物，结合至少一个醇、胺、羧酸、硫醇或其衍生物或其组合的方法。
• PYRROLOPYRAZINE INHIBITORS OF KINASES
  申请人：Penning Thomas D.

  公开号：US20110015172A1

  公开（公告）日：2011-01-20

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1a , R 1b , X, and Y are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as Cdc7 and methods of treating diseases such as cancer.

  本发明涉及式(I)的化合物或药用可接受的盐，其中R1a、R1b、X和Y在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制Cdc7等激酶并治疗癌症等疾病的方法。
• Anti-Viral Compounds
  申请人：DeGoey David A.

  公开号：US20100168138A1

  公开（公告）日：2010-07-01

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

  描述了一种有效抑制丙型肝炎病毒（“HCV”）复制的化合物。本发明还涉及制备这种化合物的方法、包含这种化合物的组合物，以及使用这种化合物治疗HCV感染的方法。

表征谱图